SP600125 inhibits Orthopoxviruses replication in a JNK1/2 -independent manner: Implication as a potential antipoxviral

Antiviral Research

Volumn 93, Issue 1, 2012, Pages 69-77

  Pereira, Anna C T C ^a   Soares Martins, Jamária A P ^a   Leite, Flávia G G ^a   Da Cruz, André F P ^a   Torres, Alice A ^a   Souto Padrón, Thais ^b   Kroon, Erna G ^a   Ferreira, Paulo C P ^a   Bonjardim, Cláudio A ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Antipoxviral; Antiviral; JNK; Morphogenesis; Poxvirus; SP600125

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE 1;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; COWPOX VIRUS; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; MATURE VIRUS; MOUSE; NONHUMAN; ORTHOPOXVIRUS; PREMEDICATION; PRIORITY JOURNAL; VACCINIA VIRUS; VIRUS INHIBITION; VIRUS LOAD; VIRUS MORPHOGENESIS; VIRUS REPLICATION;

ANIMALS; ANTHRACENES; ANTIVIRAL AGENTS; CELL LINE; CERCOPITHECUS AETHIOPS; CRICETINAE; HUMANS; MICE; MICE, INBRED BALB C; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASE 9; NIH 3T3 CELLS; ORTHOPOXVIRUS; PHOSPHORYLATION; POXVIRIDAE INFECTIONS; VERO CELLS; VIRUS REPLICATION;

COWPOX VIRUS; DNA VIRUSES; POXVIRIDAE; VACCINIA VIRUS; VACCINIA VIRUS ANKARA;

EID: 84355166373     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.10.020     Document Type: Article

References (83)

1. Andrade A.A., Silva P.N., Pereira A.C., De Sousa L.P., Ferreira P.C., Gazzinelli R.T., Kroon E.G., Ropert C., Bonjardim C.A. The vaccinia virus-stimulated mitogen-activated protein kinase (MAPK) pathway is required for virus multiplication. Biochem. J. 2004, 381:437-446.
2. Bain J., McLauchlan H., Elliott M., Cohen P. The specificities of protein kinase inhibitors: an update. Biochem. J. 2003, 371:199-204.
3. Bain J., Plater L., Elliott M., Shapiro N., Hastie C.J., McLauchlan H., Klevernic I., Arthur J.S., Alessi D.R., Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 2007, 408:297-315.
4. Barquet N., Domingo P. Smallpox: the triumph over the most terrible of the ministers of death. Ann. Intern. Med. 1997, 127:635-642.
5. Begleiter A., Lin D., Larson K.K., Lang J., Wu X., Cabral T., Taylor H., Guziec L.J., Kerr P.D., Hasinoff B.B., Guziec F.S. Structure-activity studies with cytotoxic anthrapyrazoles. Oncol. Rep. 2006, 15:1575-1580.
6. Bennett B.L., Sasaki D.T., Murray B.W., O'Leary E.C., Sakata S.T., Xu W., Leisten J.C., Motiwala A., Pierce S., Satoh Y., Bhagwat S.S., Manning A.M., Anderson D.W. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. USA 2001, 98:13681-13686.
7. Bennett B.L. C-Jun N-terminal kinase-dependent mechanisms in respiratory disease. Eur. Respir. J. 2006, 28:651-661.
8. Becker M.N., Obraztsova M., Kern E.R., Quenelle D.C., Keith K.A., Prichard M.N., Luo M., Moyer R.W. Isolation and characterization of cidofovir resistant vaccinia viruses. Virol. J. 2008, 5:58.
9. Bogoyevitch M.A., Boehm I., Oakley A., Ketterman A.J., Barr R.K. Targeting the JNK MAPK cascade for inhibition: basic science and therapeutic potential. Biochim. Biophys. Acta 2004, 1697:89-101.
10. Bogoyevitch M.A., Arthur P.G. Inhibitors of c-Jun N-terminal kinases: JuNK no more?. Biochim. Biophys. Acta 2008, 1784:76-93.
11. Chen S.Y., Lu J., Shih Y.C., Tsai C.H. Epstein-Barr virus latent membrane protein 2A regulates c-Jun protein through extracellular signal-regulated kinase. J. Virol. 2002, 76:9556-9561.
12. Condit R.C., Moussatche N., Traktman P. In a nutshell: structure and assembly of the vaccinia virion. Adv. Virus Res. 2006, 66:31-124.
13. da Fonseca F.G., Wolffe E.J., Weisberg A., Moss B. Effects of deletion or stringent repression of the H3L envelope gene on vaccinia virus replication. J. Virol. 2000, 74:7518-7528.
14. da Silva P.N., Soares J.A., Brasil B.S., Nogueira S.V., Andrade A.A., de Magalhaes J.C., Bonjardim M.B., Ferreira P.C., Kroon E.G., Bruna-Romero O., Bonjardim C.A. Differential role played by the MEK/ERK/EGR-1 pathway in orthopoxviruses vaccinia and cowpox biology. Biochem. J. 2006, 398:83-95.
15. Damaso C.R., Esposito J.J., Condit R.C., Moussatche N. An emergent poxvirus from humans and cattle in Rio de Janeiro State: Cantagalo virus may derive from Brazilian smallpox vaccine. Virology 2000, 277:439-449.
16. 2-terminal kinase is crucially involved in renal tubulo-interstitial inflammation. J. Pharmacol. Exp. Ther. 2009, 331:896-905.
17. De Clercq E. Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Trends Pharmacol. Sci. 2002, 23:456-458.
18. De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin. Microbiol. Rev. 2003, 16:569-596.
19. de Magalhães J.C., Andrade A.A., Silva P.N., Sousa L.P., Ropert C., Ferreira P.C., Kroon E.G., Gazzinelli R.T., Bonjardim C.A. A mitogenic signal triggered at an early stage of vaccinia virus infection: implication of MEK/ERK and protein kinase A in virus multiplication. J. Biol. Chem. 2001, 276:38353-38360.
20. Domi A., Beaud G. The punctate sites of accumulation of vaccinia virus early proteins are precursors of sites of viral DNA synthesis. J. Gen. Virol. 2000, 81:1231-1235.
21. Dong C., Yang D.D., Tournier C., Whitmarsh A.J., Xu J., Davis R.J., Flavell R.A. JNK is required for effector T-cell function but not for T-cell activation. Nature 2000, 405:91-94.
22. Fenner, F., Anderson, D.A., Arita, I., Jezek, Z., Ladnyi, I.D., 1988. Smallpox and its eradication. World Health Organization.
23. Fonseca F.G., Lanna M.C., Campos M.A., Kitajima E.W., Peres J.N., Golgher R.R., Ferreira P.C., Kroon E.G. Morphological and molecular characterization of the poxvirus BeAn 58,058. Arch. Virol. 1998, 143:1171-1186.
24. Formenty P., Muntasir M.O., Damon I., Chowdhary V., Opoka M.L., Monimart C., Mutasim E.M., Manuguerra J.C., Davidson W.B., Karem K.L., Cabeza J., Wang S., Malik M.R., Durand T., Khalid A., Rioton T., Kuong-Ruay A., Babiker A.A., Karsani M.E., Abdalla M.S. Human monkeypox outbreak caused by novel virus belonging to Congo Basin clade, Sudan, 2005. Emerg. Infect. Dis. 2010, 16:1539-1545.
25. Frischknecht F., Cudmore S., Moreau V., Reckmann I., Rottger S., Way M. Tyrosine phosphorylation is required for actin-based motility of vaccinia but not Listeria or Shigella. Curr. Biol. 1999, 9:89-92.
26. Gao Y., Signore A.P., Yin W., Cao G., Yin X.M., Sun F., Luo Y., Graham S.H., Chen J. Neuroprotection against focal ischemic brain injury by inhibition of c-Jun N-terminal kinase and attenuation of the mitochondrial apoptosis-signaling pathway. J. Cereb. Blood Flow Metab. 2005, 25:694-712.
27. Guan Q.H., Pei D.S., Liu X.M., Wang X.T., Xu T.L., Zhang G.Y. Neuroprotection against ischemic brain injury by SP600125 via suppressing the extrinsic and intrinsic pathways of apoptosis. Brain Res. 2006, 1092:36-46.
28. Gunawan B.K., Liu Z.X., Han D., Hanawa N., Gaarde W.A., Kaplowitz N. C-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity. Gastroenterology 2006, 131:165-178.
29. Gupta N., Bhaskar A.S., Lakshmana Rao P.V. Transcriptional regulation and activation of the mitogen-activated protein kinase pathway after Japanese encephalitis virus infection in neuroblastoma cells. FEMS Immunol. Med. Microbiol. 2011, 62:110-121.
30. Hamza M.S., Reyes R.A., Izumiya Y., Wisdom R., Kung H.J., Luciw P.A. ORF36 protein kinase of Kaposi's sarcoma herpesvirus activates the c-Jun N-terminal kinase signaling pathway. J. Biol. Chem. 2004, 279:38325-38330.
31. Han Y.L., Qi Y.M., Kang J., Liang M., Chen X.H. Role of MAPK in the migration of human coronary artery smooth muscle cell into three-dimensional fibrin gel. Zhongguo Ying Yong Sheng Li Xue Za Zhi 2005, 21:388-392.
32. Hassan M., Ghozlan H., Abdel-Kader O. Activation of c-Jun NH2-terminal kinase (JNK) signaling pathway is essential for the stimulation of hepatitis C virus (HCV) non-structural protein 3 (NS3)-mediated cell growth. Virology 2005, 333:324-336.
33. Holloway G., Coulson B.S. Rotavirus activates JNK and p38 signaling pathways in intestinal cells, leading to AP-1-driven transcriptional responses and enhanced virus replication. J. Virol. 2006, 80:10624-10633.
34. Holm T.M., Habashi J.P., Doyle J.J., Bedja D., Chen Y., van Erp C., Lindsay M.E., Kim D., Schoenhoff F., Cohn R.D., Loeys B.L., Thomas C.J., Patnaik S., Marugan J.J., Judge D.P., Dietz H.C. Noncanonical TGFbeta signaling contributes to aortic aneurysm progression in Marfan syndrome mice. Science 2011, 332:358-361.
35. Hu Y.B., Liu X.Y. Protective effects of SP600125 in a diet-induced rat model of non-alcoholic steatohepatitis. Scand. J. Gastroenterol. 2009, 44:1356-1362.
36. Ikezumi Y., Hurst L., Atkins R.C., Nikolic-Paterson D.J. Macrophage-mediated renal injury is dependent on signaling via the JNK pathway. J. Am. Soc. Nephrol. 2004, 15:1775-1784.
37. Jordan R., Tien D., Bolken T.C., Jones K.F., Tyavanagimatt S.R., Strasser J., Frimm A., Corrado M.L., Strome P.G., Hruby D.E. Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrob. Agents Chemother. 2008, 52:1721-1727.
38. Jordan R., Chinsangaram J., Bolken T.C., Tyavanagimatt S.R., Tien D., Jones K.F., Frimm A., Corrado M.L., Pickens M., Landis P., Clarke J., Marbury T.C., Hruby D.E. Safety and pharmacokinetics of the antiorthopoxvirus compound ST-246 following repeat oral dosing in healthy adult subjects. Antimicrob. Agents Chemother. 2010, 54:2560-2566.
39. Jesus D.M., Costa L.T., Goncalves D.L., Achete C.A., Attias M., Moussatche N., Damaso C.R. Cidofovir inhibits genome encapsidation and affects morphogenesis during the replication of vaccinia virus. J. Virol. 2009, 83:11477-11490.
40. Joklik W.K. The purification for four strains of poxvirus. Virology 1962, 18:9-18.
41. Kerkelä R., Grazette L., Yacobi R., Iliescu C., Patten R., Beahm C., Walters B., Shevtsov S., Pesant S., Clubb F.J., Rosenzweig A., Salomon R.N., Van Etten R.A., Alroy J., Durand J.B., Force T. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat. Med. 2006, 12:908-916.
42. Lin S., Chen W., Broyles S.S. The vaccinia virus B1R gene product is a serine/threonine protein kinase. J. Virol. 1992, 66:2717-2723.
43. Lin S., Broyles S.S. Vaccinia protein kinase 2: a second essential serine/threonine protein kinase encoded by vaccinia virus. Proc. Natl. Acad. Sci. USA 1994, 91:7653-7657.
44. Manning A.M., Davis R.J. Targeting JNK for therapeutic benefit: from junk to gold?. Nat. Rev. Drug. Discov. 2003, 2:554-565.
45. McNulty S., Bornmann W., Schriewer J., Werner C., Smith S.K., Olson V.A., Damon I.K., Buller R.M., Heuser J., Kalman D. Multiple phosphatidylinositol 3-kinases regulate vaccinia virus morphogenesis. PLoS One 2010, 5:e10884.
46. Mehrotra S., Chhabra A., Hegde U., Chakraborty N.G., Mukherji B. Inhibition of c-Jun N-terminal kinase rescues influenza epitope-specific human cytolytic T lymphocytes from activation-induced cell death. J. Leukoc. Biol. 2007, 81:539-547.
47. Mercer J., Helenius A. Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cells. Science 2008, 320:531-535.
48. Mizutani T., Fukushi S., Saijo M., Kurane I., Morikawa S. JNK and PI3k/Akt signaling pathways are required for establishing persistent SARS-CoV infection in Vero E6 cells. Biochim. Biophys. Acta 2005, 1741:4-10.
49. Moss, B. 2007. Poxviridae, In: Fields, B.N., Knipe, D.M., Howley, P.M. (Ed.), Virology, fifth ed, vol. 2. Lippincott-Raven, Philadelphia. pp. 2905-2946.
50. Perkins D., Gyure K.A., Pereira E.F., Aurelian L. Herpes simplex virus type 1-induced encephalitis has an apoptotic component associated with activation of c-Jun N-terminal kinase. J. Neurovirol. 2003, 9:101-111.
51. Quenelle D.C., Buller R.M., Parker S., Keith K.A., Hruby D.E., Jordan R., Kern E.R. Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob. Agents Chemother. 2007, 51:689-695.
52. Ravanello M.P., Hruby D.E. Conditional lethal expression of the vaccinia virus L1R myristylated protein reveals a role in virion assembly. J. Virol. 1994, 68:6401-6410.
53. Reeves P.M., Bommarius B., Lebeis S., McNulty S., Christensen J., Swimm A., Chahroudi A., Chavan R., Feinberg M.B., Veach D., Bornmann W., Sherman M., Kalman D. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat. Med. 2005, 11:731-739.
54. Reeves P.M., Smith S.K., Olson V.A., Thorne S.H., Bornmann W., Damon I.K., Kalman D. Variola and monkeypox viruses utilize conserved mechanisms of virion motility and release that depend on abl and SRC family tyrosine kinases. J. Virol. 2011, 85:21-31.
55. Rempel R.E., Anderson M.K., Evans E., Traktman P. Temperature-sensitive vaccinia virus mutants identify a gene with an essential role in viral replication. J. Virol. 1990, 64:574-583.
56. Rempel R.E., Traktman P. Vaccinia virus B1 kinase: phenotypic analysis of temperature-sensitive mutants and enzymatic characterization of recombinant proteins. J. Virol. 1992, 66:4413-4426.
57. Resch W., Weisberg A.S., Moss B. Vaccinia virus nonstructural protein encoded by the A11R gene is required for formation of the virion membrane. J. Virol. 2005, 79:6598-6609.
58. Reynolds M.G., Cono J., Curns A., Holman R.C., Likos A., Regnery R., Treadwell T., Damon I. Human monkeypox. Lancet Infect. Dis. 2004, 4:604-605.
59. Roberts P.J., Der C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291-3310.
60. Sbrana E., Xiao S.Y., Newman P.C., Tesh R.B. Comparative pathology of North American and central African strains of monkeypox virus in a ground squirrel model of the disease. Am. J. Trop. Med. Hyg. 2007, 76:155-164.
61. Sejvar J.J., Chowdary Y., Schomogyi M., Stevens J., Patel J., Karem K., Fischer M., Kuehnert M.J., Zaki S.R., Paddock C.D., Guarner J., Shieh W.J., Patton J.L., Bernard N., Li Y., Olson V.A., Kline R.L., Loparev V.N., Schmid D.S., Beard B., Regnery R.R., Damon I.K. Human monkeypox infection: a family cluster in the midwestern United States. J. Infect. Dis. 2004, 190:1833-1840.
62. Sharma N., Deshmukh R., Bedi K.L. SP600125, a competitive inhibitor of JNK attenuates streptozotocin induced neurocognitive deficit and oxidative stress in rats. Pharmacol. Biochem. Behav. 2010, 96:386-394.
63. Smee D.F., Sidwell R.W., Kefauver D., Bray M., Huggins J.W. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob. Agents Chemother. 2002, 46:1329-1335.
64. Smith G.L., McFadden G. Smallpox: anything to declare?. Nat. Rev. Immunol. 2002, 2:521-527.
65. Soares J.A., Leite F.G., Andrade L.G., Torres A.A., De Sousa L.P., Barcelos L.S., Teixeira M.M., Ferreira P.C., Kroon E.G., Souto-Padron T., Bonjardim C.A. Activation of the PI3K/Akt pathway early during vaccinia and cowpox virus infections is required for both host survival and viral replication. J. Virol. 2009, 83:6883-6899.
66. Song Z.F., Ji X.P., Li X.X., Wang S.J., Wang S.H., Zhang Y. Inhibition of the activity of poly (ADP-ribose) polymerase reduces heart ischaemia/reperfusion injury via suppressing JNK-mediated AIF translocation. J. Cell. Mol. Med. 2008, 12:1220-1228.
67. Syrkina O.L., Quinn D.A., Jung W., Ouyang B., Hales C.A. Inhibition of JNK activation prolongs survival after smoke inhalation from fires. Am. J. Physiol. Lung Cell. Mol. Physiol. 2007, 292:984-991.
68. 2-terminal kinase, SP600125, protects mice from d-galactosamine/lipopolysaccharide-induced hepatic failure by modulating BH3-only proteins. Life Sci. 2007, 80:1335-1344.
69. Tolomeo M., Dieli F., Gebbia N., Simoni D. Tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Anticancer Agents Med. Chem. 2009, 9:853-863.
70. Tournier C., Hess P., Yang D.D., Xu J., Turner T.K., Nimnual A., Bar-Sagi D., Jones S.N., Flavell R.A., Davis R.J. Requirement of JNK for stress-induced activation of the cytochrome c-mediated death pathway. Science 2000, 288:870-874.
71. Traktman P., Anderson M.K., Rempel R.E. Vaccinia virus encodes an essential gene with strong homology to protein kinases. J. Biol. Chem. 1989, 264:21458-21461.
72. Traktman P., Caligiuri A., Jesty S.A., Liu K., Sankar U. Temperature-sensitive mutants with lesions in the vaccinia virus F10 kinase undergo arrest at the earliest stage of virion morphogenesis. J. Virol. 1995, 69:6581-6587.
73. Trindade G.S., Emerson G.L., Carroll D.S., Kroon E.G., Damon I.K. Brazilian vaccinia viruses and their origins. Emerg. Infect. Dis. 2007, 13:965-972.
74. Unger B., Traktman P. Vaccinia virus morphogenesis: a13 phosphoprotein is required for assembly of mature virions. J. Virol. 2004, 78:8885-8901.
75. Vivanco I., Palaskas N., Tran C., Finn S.P., Getz G., Kennedy N.J., Jiao J., Rose J., Xie W., Loda M., Golub T., Mellinghoff I.K., Davis R.J., Wu H., Sawyers C.L. Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. Cancer Cell 2007, 11:555-569.
76. Vorou R.M., Papavassiliou V.G., Pierroutsakos I.N. Cowpox virus infection: an emerging health threat. Curr. Opin. Infect. Dis. 2008, 21:153-156.
77. Wang S., Shuman S. Vaccinia virus morphogenesis is blocked by temperature-sensitive mutations in the F10 gene, which encodes protein kinase 2. J. Virol. 1995, 69:6376-6388.
78. Wang Y., Zhang Y., Wei Z., Li H., Zhou H., Zhang Z. JNK inhibitor protects dopaminergic neurons by reducing COX-2 expression in the MPTP mouse model of subacute Parkinson's disease. J. Neurol. Sci. 2009, 285:172-177.
79. Wickramasekera N.T., Traktman P. Structure/function analysis of the vaccinia virus F18 phosphoprotein, an abundant core component required for virion maturation and infectivity. J. Virol. 2010, 84:6846-6860.
80. Wolf D., Rumpold H. A benefit-risk assessment of imatinib in chronic myeloid leukaemia and gastrointestinal stromal tumours. Drug Safety 2009, 32:1001-1015.
81. Yang G., Pevear D.C., Davies M.H., Collett M.S., Bailey T., Rippen S., Barone L., Burns C., Rhodes G., Tohan S., Huggins J.W., Baker R.O., Buller R.L., Touchette E., Waller K., Schriewer J., Neyts J., De Clercq E., Jones K., Hruby D., Jordan R. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J. Virol. 2005, 79:13139-13149.
82. Yang H., Kim S.K., Kim M., Reche P.A., Morehead T.J., Damon I.K., Welsh R.M., Reinherz E.L. Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction. J. Clin. Invest. 2005, 115:379-387.
83. Zapata H.J., Nakatsugawa M., Moffat J.F. Varicella-zoster virus infection of human fibroblast cells activates the c-Jun N-terminal kinase pathway. J. Virol. 2007, 81:977-990.